In a report released today, Brian Drab from William Blair maintained a Buy rating on Novanta (NOVT – Research Report). The company’s shares ...

William Blair analyst Adam Klauber maintained a Buy rating on Baldwin Insurance Group (BWIN – Research Report) today. The company’s shares ...

William Blair reiterated their market perform rating on shares of Nektar Therapeutics (NASDAQ:NKTR – Free Report) in a report issued on Tuesday,RTT News reports. Other research analysts have also ...

Stock analysts at William Blair lowered their Q1 2025 EPS estimates for shares of AMN Healthcare Services in a report issued ...

Fintel reports that on February 21, 2025, William Blair downgraded their outlook for CACI International (NYSE:CACI) from ...

Fintel reports that on February 21, 2025, William Blair downgraded their outlook for Booz Allen Hamilton Holding (NYSE:BAH) ...

William Blair downgrades Booz Allen, CACI International, Leidos, Parsons and General Dynamics on the heightened risk of ...

Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...

Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

We recently compiled a list of the 10 AI News and Ratings Making Waves on Wall Street. In this article, we are going to take ...

Insulet Corporation (NASDAQ:PODD) reported fourth-quarter adjusted EPS of $1.15, down from $1.40 a year ago but beating the ...

Fintel reports that on February 21, 2025, William Blair downgraded their outlook for General Dynamics (WBAG:GEDY) from Outperform to Market Perform. There are 2,727 funds or institutions reporting ...